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Regular Article
IMMUNOBIOLOGY
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Key Points
• The frequency of CD161
MAIT cells is dramatically de-
creased in the blood of HIV-
infected patients, and they are
nonrecoverable with HAART.
• Gut sequestration and apopto-
sis in response to bacterial
signals may, amongst others,
be mechanisms that contrib-
ute to this.
HIV infection is associated with immune dysfunction, perturbation of immune-cell
subsets and opportunistic infections. CD161CD8 T cells are a tissue-infiltrating
population that produce IL17A, IL22, IFN, and TNF, cytokines important in mucosal
immunity. In adults they dominantly express the semi-invariant TCR V7.2, the canoni-
cal feature of mucosal associated invariant T (MAIT) cells and have been recently
implicated in host defense against pathogens. We analyzed the frequency and function
of CD161/MAIT cells in peripheral blood and tissue from patients with early stage or
chronic-stage HIV infection. We show that the CD161/MAIT cell population is
significantly decreased in early HIV infection and fails to recover despite otherwise
successful treatment. We provide evidence that CD161/MAIT cells are not preferen-
tially infected but may be depleted through diverse mechanisms including accumulation
in tissues and activation-induced cell death. This loss may impact mucosal defense and
could be important in susceptibility to specific opportunistic infections in HIV. (Blood.
2013;121(6):951-961)
Introduction
The natural course of human immunodeficiency virus type 1
(HIV-1) infection is associated with progressive immune dysfunc-
tion, perturbation of immune-cell subsets and increased opportunis-
tic infections. In early disease, there is a dramatic loss of CD4
T cells from the gastrointestinal tract resulting in impaired mucosal
immunity, reduced peripheral CD4 T-cell count, and increased
systemic T-cell activation.1-4 These factors contribute to an in-
creased susceptibility to infection with specific organisms such as
Mycobacterium tuberculosis and Candida albicans.5-7 In addition,
more recent evidence suggests an important role for the loss of
CD8 T cells in susceptibility to bacterial pneumonia and all-cause
mortality in HIV infection.8
MAIT cells are a distinct subset of tissue-infiltrating lympho-
cytes with antibacterial functions that account for up to one-third of
the CD8 T-cell population in the blood of healthy individuals.9-11
MAIT cells are identified by expression of a semi-invariant T-cell
receptor (TCR), iV7.2,10,12,13 which recognizes ligands presented
by MHC class I related (MR1) protein.14 MR1 presentation occurs
on dendritic cells, monocytes, and lung epithelial cells in response
to bacterial pathogens.9,10,12 MAIT cells are activated in vitro in an
MR1-dependent fashion by a range of bacterial and fungal
pathogens, including Escherichia coli, M tuberculosis, and C albi-
cans,9,10 and in mouse models have been shown to provide
protection against bacterial infection.10,15 In addition, MAIT cells
have been shown to be lost from the blood and present in the lungs
of patients with active tuberculosis, suggesting they may play an
important role in host immunity to M tuberculosis.9,10
Specific subsets of CD4 and CD8 T cells, termed Th17 and
Tc17, are defined by their ability to produce IL17A and are
important in the regulation of mucosal integrity and antibacterial
immunity.16-20 Early in HIV infection, Th17 cells are lost from
the gastrointestinal tract, but may be restored through long-term
highly active antiretroviral therapy (HAART) concurrent with a
reduction in immune activation levels.21 The loss of this IL17A and
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IL22-producing cell population during untreated HIV infection has
been shown to impact on mucosal immunity and pathogen dissemi-
nation from the gut, suggesting a protective role for such cells in
HIV infection.22
Recent work from our group and others has revealed an
important intersection in humans between MAIT cells, Tc17 cell
populations, and expression of the C-type lectin CD161.11,12 CD8
T cells expressing high levels of CD161 exhibit a distinct
phenotype associated with RORt expression, accompanied by
IL17/22 production.11 The CD161CD8 T-cell population is
detectable in cord blood, where it exhibits a similar transcriptional
profile to that of adult cells; expansion and narrowing of TCR usage
toward a V7.2 MAIT phenotype occurs with age.12,13 Thus in
adults the CD161CD8 T-cell population is dominated by cells
bearing the canonical V7.2 TCR (MAIT; 80%-90%).12,13 In this
study, for simplicity, we have described this CD161CD8 T-cell
population as CD161/MAIT cells, although minority MAIT cell
populations exist which do not express CD8.10,23
The in vivo significance of CD161/MAIT cells is not yet
known but the potential impact on AIDS pathogenesis is substan-
tial. Their prominent homing capacity for mucosal tissue suggests
they may play a role in mucosal defense against pathogens.
Furthermore, CD161/MAIT cells may play a role in intestinal
defense, where loss in HIV may be relevant to bacterial transloca-
tion and immune activation.
We hypothesized that the CD161/MAIT population would
be disturbed in HIV infection, linked to enhanced susceptibility
to specific mucosal infections. We provide evidence for a major,
early, and sustained impact of HIV on this unique and prominent
T-cell subset.
Methods
Cohorts
Healthy donors (n 23) were non–HIV-tested laboratory volunteers and
leukocyte cones supplied by the local health authority. Patients chronically
infected with HIV were from the King’s College London Infectious
Diseases Biobank (n 13) or the Thames Valley cohort (n 10) and were
sampled between 1 and 15 years after diagnosis. Patients with early HIV
infection were randomly chosen baseline samples from the SPARTAC
cohort (n  35). A separate cohort of treatment-naive patients from the
Swiss HIV Cohort Study (n  29) were sampled before, 1 and 2 years into
HAART. Induction of apoptosis was assessed in samples from the
Swiss-Spanish Intermittent Treatment Trial (SSITT; n 10). All HIV
patients were HCV and HBV-negative at the time of sampling.
Colon biopsies (30cm from the anal margin) were collected from HIV
patients at the Chelsea and Westminster Hospital (n 12) who were
undergoing colonoscopy as part of their routine clinical care. Indications for
colonoscopy were diarrhea (n 5), rectal bleeding (n 3), abdominal pain
(n  2), iron deficiency anemia (n  1), and surveillance of polyps (n  1).
The colon of all patients had a normal endoscopic appearance. Four patients
were taking HAART at the time of biopsy and 7 had nonspecific
colitis/inflammatory infiltrate (referred to in the text as nonspecific colitis),
which is common in HIV infection.24-26 Normal noninflamed surgically
resected tissue from the rectosigmoid or descending colon of age-matched
controls was obtained from the Oxford Pathology/GI Biobank.
Gut specimens for isolation of lamina propria mononuclear cells
(LPMCs) were taken from patients recruited from the Gastroenterology
Unit and Colorectal Surgery Department at the John Radcliffe Hospital,
Oxford. All tissue samples were taken from macroscopically healthy and
noninflamed colon of colorectal cancer or IBD patients undergoing surgery.
The clinical data of the HIV-infected patients used in this study are
provided in supplemental Tables 1 through 3 (available on the Blood Web
site; see the Supplemental Materials link at the top of the online article).
Flow cytometry
Whole blood was either stained directly and the erythrocytes lysed with BD
FACS lysing solution (BD Bioscience) before analysis or peripheral blood
mononuclear cells (PBMCs) were isolated using Lymphoprep (AxisShield).
LPMCs were isolated as previously described.27 For intracellular staining,
PBMCs were then stimulated with PMA (250 ng/mL) and ionomycin
(500 ng/mL) for 6 hours or left unstimulated. Brefeldin A (Sigma-Aldrich)
was added at 1 g/mL 5 hours before the end of stimulation.
All antibodies were from BD Bioscience unless otherwise indicated.
Dead cell were excluded with Near-IR Dead Cell Stain (Invitrogen).
Antibodies used were: CD3 Pacific Orange (UCHT1, Invitrogen) or
eFluor605 (OKT3, eBioscience), CD4 eFluor650 (eBioscience), Alexa-
fluor700 (RPA-T4), QDot605 (S3.5, Invitrogen) or PECy-7 (L200), CD8
PerCP, PECy-7 (SK1) or V450 (RPA-T8), CD45 Alexafluor700 (HI30,
Biolegend), CD56 PECy-7 (B159), CD69 FITC (FN50, eBioscience),
CD161 PE, APC (191B8, Miltenyi Biotech) or PECy-7 (HP3G10, eBiosci-
ence), TCR V7.2 FITC, PE or APC (3C10, BioLegend), IFN FITC
(4S.B3), IL17A PE (eBio64CAP17, eBioscience), IL22 PerCP-eFluor710
(22URT1, eBioscience), CCR5 PE (2D7/CCR5), CXCR4 PECy-7 (12G5),
and CCR6 PerCPCy-5.5 or PECy7 (11A9), activated capsase-3 PE (C92-
605), CD95 PECy7 (DX2, Biolegend), TNFRI PE (16 803, R&D Systems),
TNFRII FITC (22 235, R&D Systems), CD261 Alexafluor488 (DR-4-02,
Serotec), CD262 PE (DJR2-4 [7-8], Biolegend), Bcl-2 FITC (Bcl2/100),
and anti–KC57-RD1 PE (FH190-1-1; Beckman Coulter). For proliferation
assays, PBMCs were stained with CellTrace Violet (Invitrogen) as per the
manufacturer’s instructions.
Data were collected on an LSRII flow cytometer (BD Biosciences) or a
MACSQuant (Miltenyi Biotec) and analyzed using FlowJo Version 9.3.1
(TreeStar).
Immunohistochemistry
Immunohistochemistry was performed on 5-m thick sections of formalin-
fixed, paraffin-embedded tissues. Heat-induced antigen retrieval was per-
formed using a pressure cooker (The Retriever, Electron Microscopy
Sciences) and R-Buffer A (lipolysaccharide) or B (MDR-1, CD3, CD8;
Electron Microscopy Sciences). Endogenous peroxidase activity was
quenched with 3% hydrogen peroxide and 0.13% sodium azide (both
Sigma-Aldrich), and sections blocked with 0.5% blocking reagent (Perkin
Elmer). Primary antibodies included anti–MDR-1 (5A12.2, mouse IgG2b,
Merck Millipore), anti-CD3 (F7.2.38, mouse IgG1, Dako) anti-CD8 (rabbit
polyclonal, Abcam), anti-lipopolysaccharide (LPS) core (WN1 222-5,
mouse IgG2A, Hycult Biotech), and isotype-matched controls. For immuno-
fluorescent staining, samples were stained sequentially, initially for MDR-1
(detected with peroxidase-conjugated donkey anti–mouse IgG secondary
(Jackson ImmunoResearch Laboratories), and then for CD3 and CD8
(detected sequentially with peroxidase-conjugated donkey anti–rabbit IgG
(Jackson ImmunoResearch Laboratories), and peroxidase-conjugated goat
anti–mouse IgG1 (Invitrogen) secondaries. Tyramide signal amplification,
with TSA-plus Cy5, Cy3, and FITC reagents (PerkinElmer), was used to
visualize staining of MDR-1, CD8, and CD3, respectively. Samples were
reblocked with hydrogen peroxide and sodium azide between each stain.
Controls for peroxidase blocking were included in all experiments. Slides
were mounted with Prolong Gold with DAPI (Invitrogen) and imaged at
room temperature on a FluoView FV1000 confocal microscope (Olympus)
using a 40/1.30 Oil UPlan FLN objective lens. Images were acquired
using FV10-ASW software. For LPS, staining was detected with N-Histofine
simple stain MAX PO (M; Nichirei) and ImmPACT DAB peroxidase
substrate, samples counterstained with hematoxylin QS and mounted with
VectaMount permanent mounting medium (all Vector Labs). Images were
collected with a Nikon Coolscope Slide Scanner (Nikon). Further detail is
provided in supplemental Methods.
Immunofluorescent images were analyzed with CellProfiler 2.0 and
CellProfiler Analyst 2.0 software (www.cellprofiler.org; Broad Institute).28
Further detail is provided in supplemental Methods. LPS cells in the
lamina propria were manually counted from randomly collected 20
magnification images; a median of 9 images was counted per slide (range
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6-14). Surface area analyzed, excluding the intestinal lumen, was calculated
in ImageJ Version 10.2 (National Institutes of Health).
In vitro stimulation of PBMCs
E coli (DH5) was fixed in 1% paraformaldehyde for 5 minutes, and
washed extensively. A negative control was prepared in identical fashion.
PBMCs were cultured for 20 hours, 44 hours, or 6 days (as noted in the
appropriate figure legends) with either paraformaldehyde-fixed E coli at the
indicated bacteria per cell (BpC) ratio or the negative control. In some
experiments, blocking antibodies against MR1 (Clone 26.5) or CD95
(ZB4, Millipore), appropriate isotype controls or recombinant human
TNFRI/TNFRSF1A Fc chimera (R&D Systems) were used. Alternatively,
PBMCs were activated with PMA (50 ng/mL) and ionomycin (250 ng/mL)
for 20 hours or with anti-CD2/CD3/CD28 microbeads (T-cell Activation/
Expansion Kit, Miltenyi Biotec) for 20 or 44 hours.
In vitro PBMC infection with HIV
PBMCs were activated with phytohemagglutinin (PHA, 1 g/mL), recom-
binant human (rh)IL2 (25 ng/mL) and rhIL7 (20 ng/mL; all Sigma-Aldrich)
for 72 hours. Activated cells were incubated with no virus, a CCR5-tropic
HIV strain (JR-CSF) or a CXCR4-tropic strain (MN) at a multiplicity of
infection (MOI) of 10 and were cultured in R10 for 9 days. RhIL2
(20 ng/mL) and rhIL7 (20 ng/mL) were further added to the cultures on
days 0, 3, and 6, and cell samples were harvested and stained for p24
expression on days 6 and 9.
Statistical analysis
Statistics were performed using GraphPad Prism Version 5.0a. Normal
distribution was determined using a Kolmogorov-Smirnov test. Differences
between groups were analyzed using student t tests, Mann-Whitney tests, or
ANOVA with Tukey or Dunnett multiple comparison tests or a test for
linear trend for posthoc analysis or Kruskal-Wallis test with Dunn posthoc
analysis where appropriate. Pearson correlation coefficients or Spearman
correlation coefficients were calculated where appropriate. All tests were
2-tailed. All data are presented as means unless otherwise indicated.
Statistical significance was accepted at P  .05.
Ethics
Samples were taken after written informed consent was given by the
participants and/or their legal guardians in accordance with the Declaration
of Helsinki and after approval from the relevant Ethical Review Boards at
all sites.
Results
E coli activates CD161CD8 T cells in a PBMC environment
The majority ( 90%) of CD161CD8 T cells express TCR
V7.2 and are thus defined as MAIT cells.13,29 In contrast, a smaller
fraction of peripheral CD8 T cells express lower levels () of
CD161; this population is phenotypically, functionally, and transcrip-
tionally distinct from the CD161 population, bearing a diverse
range of TCRs.11,13 We used the high expression of CD161 on
CD8 T cells (CD161CD8 T cells) to define the CD161/
MAIT cell population.
CD161/MAIT cells isolated from healthy subjects can be
activated by monocytes pre-exposed to a range of bacteria and
yeast, triggering up-regulation of the activation marker CD69 and
production of IFN in an MR1-dependent manner.10 Similar
findings have been reported with MAIT cell lines.9 We confirmed
this using unsorted PBMCs. PBMCs from healthy donors were
exposed to paraformaldehyde-fixed E coli for 20 hours and cyto-
kine production and CD69 expression assessed. Consistent with
previous reports we observed dose-dependent activation of the
CD161CD8 T-cell population (Figure 1A-C, supplemental
Figure 1). E coli–induced activation was restricted to
CD161CD8 T cells. Blocking of MR1 with specific antibody
inhibited E coli–induced activation in a dose-dependent manner as
measured by CD69 expression (Figure 1D) and IFN production
(not shown), confirming that in our system, activation of
CD161CD8 T cells by E coli exposure was MR1-dependent,
consistent with previous studies.10 Similar results were obtained
when gated on V7.2CD161CD8 T cells (data not shown).
CD161CD8 T cells are lost from the blood in early HIV
infection
To assess the effect of HIV infection on CD161/MAIT cells we
first compared the frequency of CD161-expressing CD8 T-cell
populations in the peripheral blood of patients recently infected
with HIV, patients chronically infected who were not currently
undergoing treatment, and healthy controls (supplemental Table 1).
The frequency of CD8 T cells expressing CD161 was markedly
reduced in patients with early (2.44%; P  .0001) or chronic
(2.38%; P  .01) HIV infection versus healthy controls (10.74%;
Figure 2A-B). This was observed in both frozen PBMCs and
freshly prepared whole blood (supplemental Figure 2A-B). The
frequency of CD161CD8 T cells did not correlate with either
viral load or CD4 count (supplemental Figure 2C-D). Some
overlap between the frequency of CD161CD8 T cells in
healthy controls and HIV-infected patients was noted, with normal
or near normal frequencies in a minority of HIV-infected individu-
als and low frequencies in some healthy controls. No changes were
noted in the non-MAIT CD161(mid) CD8 T-cell populations
(Figure 2A).
Loss of Tc17 cells in HIV infection
Consistent with previous work,11 IL17A production within the
CD8 T-cell population was primarily restricted to the
CD161CD8 T-cell population whereas IL22 and IFN produc-
tion was observed in the CD161, CD161, and CD161	
populations (Figure 2D). In agreement with the disappearance of
the CD161CD8 T-cell population from the circulating blood of
HIV patients, a lower frequency of Tc17 cells in chronically
infected patients versus healthy controls was observed (0.034%
versus 0.41%; P  .004). There was no difference in the frequency
of IL22 or IFN-producing CD8 T cells (Figure 2C-D).
CD161CD8 T cells express tissue homing markers
To determine the homing capacity of CD161/MAIT cells, we
examined expression of the tissue-homing marker CCR6, as well as
the HIV entry coreceptor molecules CCR5 and CXCR4, on
CD161CD8 T cells from healthy controls and patients with
chronic HIV infection.
In healthy controls, the majority of CD161CD8 T cells
( 85%) expressed high levels of CCR6 and CCR5 with little
CXCR4 expression evident (supplemental Figure 3A). compared
with healthy controls, HIV patients had a lower frequency of
circulating CCR6CD8 T cells (2.21% vesus 16.43%; P  .001)
with no difference in the frequency of CCR5 or CXCR4CD8
T cells. There was no difference in the frequencies of circulating
CCR6CD4 T cells (supplemental Figure 3C).
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Analysis of CD161/MAIT cells in the colon in HIV infection
Given the expression of tissue homing receptors by CD161/
MAIT cells, their steady-state enrichment in the gut,10,14 their
tendency to traffic to inflamed tissues,11 and the inflammatory
response seen in the gut in HIV infection,1,2,26,30 we investigated the
relationship between loss of CD161/MAIT cells from the blood
in HIV infection and trafficking to and retention in the gut. Colon
biopsies from 12 HIV-infected patients were compared with tissue
from age-matched controls (supplemental Table 3). Because of
technical limitations in staining of formalin-fixed paraffin-
embedded tissue with surface markers such as CD161, V7.2,
IL18R, and CCR6, CD161/MAIT cells were characterized by
the coexpression of CD3, CD8, and high-level expression of the
multi-drug efflux pump, MDR1 (Figure 3A).12,31 Although MDR1
expression is not uniquely linked to CD161 status by flow
cytometry, high levels of MDR1 are associated with CD161CD8
T cells in the intestine (supplemental Figure 4A-C). In addition,
MDR1 expression has previously been linked to CD161/MAIT
cells at the levels of transcription, protein expression, and
function.11-13,31 Although we cannot exclude contamination of the
MDR1CD8CD3 population with non-CD161/MAIT cells,
the frequency of CD3CD8MDR1 cells in healthy controls
(median 8.0% of CD3 cells, range 2.0%-22.9%) was consistent
with previous estimates of MAIT cell frequency in the intestine.12
We observed that the proportion of CD3CD8 cells expressing
MDR1 was reduced in HIV-infected patients versus controls
(14.5% versus 32.3%, P  .0024; Figure 3B). However, the
number of CD3CD8MDR1 cells/mm2 was not significantly
different between groups (226 versus 147, P  .17; Figure 3D).
This was probably because of enrichment of CD3CD8 cells,
both as a proportion of CD3 cells (67.5% versus 31.0%,
P  .0002; Figure 3C), and in absolute numbers (1687 versus
469/mm2, P  .0006; Figure 3E, supplemental Figure 5A-B).
Furthermore, although not statistically significant, both the number
of CD3CD8MDR1 and CD3CD8 cells/mm2 were lower in
patients on HAART and in patients without nonspecific colitis
Figure 1. MR1-dependent activation of CD161CD8
T cells by E coli. Healthy isolated PBMCs were exposed
to E coli overnight and analyzed for CD69 expression
and IFN and IL17A production by CD8 T cells as
described in “Methods.” (A) There was a significant
increase in the cell surface expression of CD69 on the
CD161 population in response to E coli exposure
compared with the mock-infected control and to the
CD161 and CD161	 E coli–exposed populations
(n  12). (B-C) A greater proportion of the E coli–
exposed CD161 population produced IFN or IL17A
than the CD161	 population (n  12). Note data points
lie on the x-axis (values of 0% were arbitrarily ascribed a
value of 0.01% or 0.001% so as to appear on the log
scale). (D) Increasing concentrations of anti-MR1 block-
ing antibody reduced the level of activation of the
CD161CD8 T cells compared with the isotype anti-
body (n  6). “Activation” on the y-axis is measured as a
ratio of the geometric mean fluorescent intensity of CD69
on the antibody-treated E coli–exposed CD161CD8
T cells compared with that of the E coli–exposed
CD161CD8 T cells. Plots are gated on CD8 T cells.
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(supplemental Figure 5C-F). Although there are methodologic
constraints in this approach, including variation in the exact site of
biopsy or resection and the small area of colon assessed in both the
HIV-infected (median 0.99/mm2) and control samples (me-
dian 1.54/mm2), our results were consistent with those of others
which suggest an overall increase in CD8 T-cell numbers in the
gut during HIV infection.1,3,4,32 Overall, despite the clear loss of
CD161/MAIT cells from blood, they are still detectable in gut,
as judged by analysis of CD8CD3MDR1 cells.
CD161/MAIT cells do not recover in the periphery during
treatment
To assess whether MAIT cells are restored through HAART, we
analyzed longitudinal PBMC samples from 29 treatment-naive
patients enrolled in the Swiss HIV Cohort Study (supplemental
Table 2). Samples were collected the week before starting treat-
ment, and at 1 and 2 years after starting treatment. All patients
showed complete suppression of viral load and recovery of CD4
T cells with HAART (supplemental Table 2; Figure 4A).
We confirmed the loss of CD161CD8 T cells (1.4% versus
10.74%; P  .0001), CCR6CD8 T cells (6.85% versus 11.32%;
P  .05), and Tc17 cells (0.05% versus 0.41%; P  .05) in the
pretreatment samples versus healthy controls (Figure 4B-D). We
found similar losses when gating on the V7.2CD161CD8
T-cell subset (Figure 4C). Of note, normal or near normal frequencies
were again seen in a minority of HIV-infected individuals.
Analysis over the 2-year period of treatment showed no changes
in the frequency of classic V7.2MAIT cells, CD161CD8
T cells, CCR6CD8 T cells, or Tc17 cells which remained
significantly lower than those of the healthy controls at all time
points (P  .05; Figure 4). Therefore CD161/MAIT cells are not
recovered by HAART.
Figure 2. Loss of CD161/MAIT cells in HIV infec-
tion. Isolated PBMCs from healthy controls (n  23) and
patients with early (n  35) or chronic stage HIV infection
(n  13) were stained for CD161 expression on CD8
T cells. (A) There was a lower frequency of CD161
cells in early and chronic HIV infection compared with the
healthy control cohort, with no differences seen in the
CD161 populations. Results are displayed as a propor-
tion of the CD8 T cell population. (B) Representative
FACS plots showing differences in the frequency of
CD161CD8 T cells. Plots are gated on CD3 cells.
(C-D) PBMCs from the healthy control and chronic HIV
infection cohorts were stimulated with PMA/ionomycin as
described in “Methods.” The CD8 T cells were analyzed
for production of IFN, IL17A, and IL22. The gating
strategy is shown in supplemental Figure 9a. (C) Repre-
sentative FACS plots of PMA and ionomycin stimulated
PBMCs in HIV patients and healthy subjects. Plots are
gated on CD8 T cells. (D) There were lower frequencies
of IL17A producing cells in the HIV patients but no
difference in the frequency of IFN or IL22 producing
cells. Note data points lie on the x-axis (values of 0%
were arbitrarily ascribed a value of 0.001% so as to
appear on the log scale).
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HIV does not preferentially infect CD161/MAIT cells
Infection of CD8 T cells by HIV was previously reported.24,33-35
Given the expression of the entry coreceptor CCR5, we hypoth-
esized that infection could contribute to CD161/MAIT cell
depletion. PBMCs from healthy donors were infected with either a
CCR5-tropic (JR-CSF) or CXCR4-tropic (MN) strain of HIV in
vitro. At both days 6 and 9 after infection, we observed infection of
CD8 T cells (Figure 5A-B). With both virus strains at both time
points the considerable majority of infected CD8 T cells were
CD161	, with the fewest infected cells found in the CD161
subset (Figure 5C-D). When considering the frequency of infection
within each of the CD161 populations, it was not higher in the
CD161/MAIT cell population than the CD161	 or CD161
populations (Figure 5D-E). No loss of CD161/MAIT cells
occurred in the infected cultures relative to the uninfected control
(Figure 5F). Direct exposure of PBMCs to HIV for 20 hours in
vitro failed to activate CD161/MAIT cells (data not shown).
E coli exposure triggers apoptosis of CD161/MAIT cells
Microbial translocation has been suggested to occur in HIV
infection after compromise of intestinal epithelial integrity.25,36,37
Given that CD161CD8 T cells are specifically activated by
bacteria, and are present in gut tissue (Figures 1-3 and supplemen-
tal Figure 4) we tested whether bacterial antigen was present in gut
tissue in HIV infection in vivo, and what the impact of antigen
encounter on CD161/MAIT cells was in vitro. Staining of colon
sections from HIV patients for LPS demonstrated frequent LPS
cells in the lamina propria and, in some sections, cell-free LPS
(Figure 6A-B, supplemental Figure 6A-B); this is consistent with
recent findings in SIV-infected rhesus macaques.25
E coli is known to activate CD161/MAIT cells, but whether
this might lead on to activation-induced cell death has not been
explored. Although CD161CD8 T cells proliferated in vitro on
exposure to E coli (supplemental Figure 6C-D), apoptosis was also
induced in dose-dependent manner as measured by expression of
Figure 3. CD161/MAIT cell analysis in the colon in
HIV. Sections of colon from HIV-infected patients (n  12)
or controls (n  12) were stained for CD3, CD8, and
MDR-1. CD161/MAIT cells were defined as
CD3CD8MDR1. (A) Representative images from
control (left) and HIV-infected tissue (right) are shown.
Arrows indicate CD3CD8MDR1 cells. Scale bars,
50 m. (B) The proportion of CD3CD8 cells express-
ing high () levels of MDR1 was reduced in HIV
infection. (C) The proportion of CD3 cells expressing
CD8 was increased in HIV infection. (D) No significant
difference was seen in the number of CD3CD8MDR1
cells per mm2. (E) The number of CD3CD8 cells per
mm2 was increased in HIV infection.
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activated caspase 3 at 20 hours (36.05% versus 0.45% in mock-
treated controls, P  .001; Figure 6C-D), surface expression of
phosphatidylserine at 44 hours (25.44% versus 5.49%, P  .004;
supplemental Figure 6I), and selective loss of CD161CD8
T cells from the culture at 20 and 44 hours and 6 days (Figure 6E,
supplemental Figure 6E-J). CD161CD8 T cells from patients
with HIV also underwent apoptosis on exposure to increasing doses
of E coli (supplemental Figure 6K-L). Although it is unclear to
what extent such proliferation and apoptosis may occur in vivo,
these data suggest that antigen/activation-induced cell death could
plausibly contribute to depletion of CD161/MAIT cells in HIV
infection.
Consistent with the specific activation of CD161CD8
T cells by E coli (Figure 1), induction of apoptosis by E coli was
also specific to CD161CD8 T cells as no differences in
expression of either activated caspase-3, phosphatidylserine, or
relative cell number were seen in the CD161	 or CD161CD8
T-cell populations (Figure 6C-E, supplemental Figure 6I-J). In
contrast, stimulation with PMA/ionomycin or large numbers of
anti-CD2/CD3/CD28 microbeads induced expression of activated
caspase 3 and phosphatidylserine expression in all subsets
(Figure 6C, supplemental Figure 6M-N). Apoptosis in response
to E coli was activation-induced, as blocking of MR1 signifi-
cantly reduced the proportion of CD161CD8 T cells express-
ing activated caspase-3 compared with PBMCs treated with
E coli alone (P  .0001; Figure 6F), abrogated the loss of
CD161CD8 T cells relative to the mock-treated control
(Figure 6G, supplemental Figure 6G), and inhibited E coli–
induced proliferation (supplemental Figure 6F-H).
Figure 5. CD161/MAIT cells are not preferentially infected in vitro. PBMCs
from healthy subjects (n  9) were activated with PHA, cultured in rhIL2 and rhIL7,
and infected with a CCR5-tropic virus (JR-CSF) or CXCR4 tropic virus (MN) at an
MOI of 10. FACS analysis was performed on days 6 and 9 after infection as described
in “Methods.” The gating strategy is shown in supplemental Figure 9B through D.
(A) CD8 T cells were infected at a low frequency by both viruses, with the greatest
frequency of p24 cells observed on day 6 after infection with JR-CSF. (B) Represen-
tative FACS plots of CD3 lymphocytes from day 6 after infection with JR-CSF.
(C) When gating on the total p24CD8 T cells, the majority of the infected CD8
T cells were found in the non-MAIT CD161	CD8 T-cell population on both day 6 and
day 9 after infection with JR-CSF virus. (D) Representative FACS plots of p24
staining of CD8 T cells mock infected or infected with JR-CSF. (E) Comparison of
the frequency of infection within the CD161/MAIT, and non-MAIT CD161 and
CD161	CD8 T-cell populations. CD161/MAIT cells were infected, but not more
frequently than either the non-MAIT CD161	 or CD161CD8 T-cell populations on
either day 6 or day 9 after infection with JR-CSF virus. (F) There was no significant
difference in the survival of the cells in the HIV infected cultures compared with the
uninfected cultures. Cell survival ratio was calculated by normalizing the frequency of
CD161/MAIT cells in the infected culture to that of the uninfected culture.
Figure 4. CD161/MAIT cells fail to recover with HAART. Patients with chronic-
stage HIV infection were followed for 2 years of HAART, with samples taken before
the start of treatment (T0), then at 1 year (T1) and 2 years (T2) into treatment
(n  29). PBMCs were stained for markers of interest including CD161, TCR V7.2
and CCR6, and a random selection were stimulated with PMA and ionomycin to
analyze the production of IFN, IL17A and IL22 (n  13). PBMCs from healthy
controls were stained for surface markers of interest including CD161 (n  23), TCR
V7.2 (n  15), and CCR6 (n  15) or were stimulated with PMA and ionomycin to
analyze the production of IFN, IL17A and IL22 (n  23). (A) All HIV patients
showed complete suppression of viral load and recovery of CD4 T cells over the
course of treatment. (B) There were no changes in the frequency of CD161CD8
T cells or CD161CD8 T cells during treatment. (C) CD161V7.2CD8 T cells
and IL17A-producing CD8 T cells failed to recover over the course of treatment.
Note data points in plots (B) and (C) lie on the x-axis (values of 0% were arbitrarily
ascribed a value of 0.001% or 0.0001% so as to appear on the log scale). (D) There
was a lower frequency of CCR6CD8 T cells in the HIV cohort at all treatment time
points compared with healthy controls, and this population of cells failed to recover
over the course of treatment. There was no difference in the frequency of CCR6CD4
T cells between healthy controls and the HIV cohort at any of the treatment time
points, and no change in the frequency of these cells over the course of treatment.
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To investigate the mechanism of activation-induced apopto-
sis, we assessed changes in death receptor expression and the
anti-apoptotic factor Bcl-2 after exposure to E coli. Marked
up-regulation of Fas (CD95) and TNFRII was seen; small increases
in the expression of DR4, which binds TRAIL, and Bcl-2 were
also noted (supplemental Figure 7A-L). Combined blockade of
Figure 6. E coli exposure triggers apoptosis and destruction of CD161/MAIT cells in vitro. (A-B) Sections of colon from HIV-infected patients (n  12) or controls
(n  12) were stained for lipopolysaccharide (LPS). (A) Representative images from control (left) and HIV-infected tissue (right) are shown. Scale bars, 50 m. (B) Significantly
more LPS cells were seen in the lamina propria in HIV infection. The number of LPS cells in the lamina propria was determined by manual counting as outlined in “Methods.”
(C-G) PBMCs from healthy subjects (n  12) were activated with PFA-fixed E coli at a bacteria per cell (BpC) ratio of 1, 10, or 100 or mock-treated and were analyzed after
20 hours incubation. (C) E coli–exposed CD161CD8 cells (BpC of 10) had higher frequencies of activated caspase-3–positive cells versus mock-treated cells or
E coli–exposed CD161	 and CD161 cell populations. (D) Representative FACS plots, gated on CD8 T cells, comparing activated caspase-3 expression in
mock-treated and E coli–exposed PBMC cultures. (E) At all BpC of E coli, there was a reduction in survival of the CD161CD8 T-cell population. No significant
differences were noted in the CD161 or the CD161	CD8 T-cell populations. Cell survival was determined by normalizing the frequency of the cell population of
interest in the E coli–exposed culture to that in the mock-treated culture. A value of 1 is equivalent to 100% survival. (F) Anti-MR1–blocking antibody reduced the
frequency of activated caspase-3–positive CD161CD8 T cells compared with the isotype control. Blocking of E coli–induced apoptosis was determined by normalizing the
frequency of activated caspase 3 CD161C8 T cells treated as indicated to that of the culture exposed to E coli alone. (G) Anti-MR1–blocking antibody increased the
survival of CD161CD8 T cells in the E coli–exposed culture. Cell survival was determined by normalizing the frequency of CD161CD8 T cells in the antibody treated,
E coli–exposed culture to that of the mock-treated culture.
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both CD95 and TNF reduced the percentage of phosphatidyl-
serine CD161CD8 T cells but had no effect on the
expression of activated caspase 3 or the loss of cells (supplemen-
tal Figure 7M-O).
Discussion
In this study, we demonstrated a specific decrease in the size of
the CD161/MAIT cell population in the blood of early and
late-stage untreated HIV patients. Interestingly, these popula-
tions are not reconstituted in the blood during 2 years of HAART.
We addressed potential mechanisms of loss from the bloodstream
in HIV infection, including redistribution to tissues, and death via
either direct viral infection or activation-induced apoptosis on
encounter with translocated bacteria.
It should be noted that in healthy individuals the size of the
CD161/MAIT cell population varies considerably, both between
individuals and with age.13 In some healthy individuals the
frequency of CD161/MAIT cells is as low as that observed in
HIV infected patients (Figure 2A-C). Furthermore, normal or near
normal frequencies of CD161/MAIT cells were seen in a
minority of HIV-infected individuals, The reason for this variation
and the impact of low CD161/MAIT cell numbers in health is
unclear.
The reduced frequency of CD161/MAIT cells in blood in
HIV infection is unlikely to be because of dilution by HIV or
herpesvirus-specific CD8 T cells. Firstly, no difference was
observed in the frequency of CD161CD8 T cells, despite the
majority of HIV, CMV, and EBV-specific CD8 T cells being
CD161 negative (data not shown).38 Secondly, despite the decrease
in frequency of HIV-specific CD8 T cells reported with
HAART,39,40 we observed no change in the frequency of CD161/
MAIT cells. Although loss secondary to HIV infection is the
probable explanation for our findings, it is not possible to exclude
that low CD161/MAIT cell frequency may predispose to HIV
infection.
Several groups have now consistently found that CD161/
MAIT cells produce a variety of cytokines, including IL17A and
IL22,11,12 cytokines known to be important in mucosal immu-
nity16,18 and to play a central role in the control of some
HIV-associated infections.20,22,41,42 We showed a specific loss of the
IL17A-producing CD161/MAIT cell population from the blood
of HIV-infected patients. The loss of Tc17 cells from the blood-
stream has recently been reported in SIV-infected rhesus macaques
with end-stage disease, but not in sooty mangabeys.43 This may
suggest a role for Tc17 cells in disease pathology. Furthermore, the
authors found similar losses of Tc17 cells in the colorectal mucosa,
liver, spleen, and axillary lymph nodes of SIV-infected macaques,
suggesting a system-wide loss of these cells in chronic infection.
CD161/MAIT cells express the mucosal tissue homing
markers CCR2, CXCR6, and CCR6, but not the lymph node
homing markers CD62L and CCR7.11,12 CCL20, the ligand for
CCR6, is expressed by healthy and inflamed intestinal mucosa in
humans.44,45 Gut-associated lymphoid tissue (GALT) is a major site
of infection and inflammation in early HIV infection1,2,26,46 and
CCL20 has been shown in the colon and jejunum of SIV-infected
macaques.47 We therefore sought to identify CD161/MAIT cells
in gut tissue in healthy controls and in subjects chronically infected
with HIV. We were limited in the analysis of gut tissue because
many relevant markers of CD161/MAIT cells could not be
reliably stained in formalin-fixed paraffin-embedded tissue, and we
used high-level expression of the transporter protein MDR1 as a
surrogate for high-level expression of CD161. Given these limita-
tions, we did not see specific enrichment of CD161/MAIT cells
in the colon, although, an absolute increase in the numbers of
CD161/MAIT cells, which resolves with HAART, or changes in
V7.2-expressing cells within the CD161 subset cannot be
excluded. Interestingly, there was no specific loss of CCR6CD4
T cells from the blood, which argues against CCL20-mediated
T-cell retention in tissue.
One possible explanation for our data are that after recruitment
to tissues, CD161/MAIT cells die through a variety of mecha-
nisms, including antigen-induced cell death (AICD), bystander
activation, or infection. Regarding AICD, recent work has shown
that MAIT cells are activated by a range of bacteria and fungi in an
MR1-dependent manner.9,10 Given the increased permeability of
the gut in HIV infection and the associated microbial
translocation,25,36,37,48-50 we first analyzed gut samples to seek
evidence for local accumulation of bacterial antigen. Immunohisto-
chemical staining of colon biopsies demonstrated significant num-
bers of LPS cells, suggesting a high antigen burden. On in vitro
activation of PBMCs by paraformaldehyde-fixed E coli, CD161/
MAIT cells specifically underwent apoptosis in a dose and
MR1-dependent manner. Some specific proliferation in vitro in
response to E coli was also observed, although again this was
reduced at the highest dose, suggesting that there is a balance
between proliferation and cell death. Up-regulation of CD95 and
TNFRII expression by E coli–exposed CD161/MAIT cells and
the partial inhibition of apoptosis with dual blockade suggest a
possible mechanism for cell death. Although these in vitro experi-
ments may not accurately reflect what is occurring in vivo, the
accumulation of apoptotic CCR6CD8 T cells in the spleens of
HIV infected patients51 and the observed loss of Tc17 cells in
macaques in all tissues studied43 are consistent with the idea that
apoptosis in tissues contributes to the observed depletion of
CD161/MAIT cells in the blood.
Given the majority of the CD161/MAIT cell population
express CCR5 and that R5-tropic viruses are dominant in early HIV
infection52,53 we investigated whether the loss of this subset could
be because of preferential infection by HIV. Previous studies have
shown infection of CD8 T cells by HIV or SIV ex vivo and
in vitro, albeit at low frequencies.24,33-35 Although we were able to
show that both CCR5 and CXCR4-tropic viruses could infect
CD8 T cells in vitro, the frequency of infection was low despite a
high viral MOI. Considering the potential of the CD161/MAIT
cells to traffic to sites of inflammation11 in early HIV infection, and
the high viral titers present in such locations,46 infection of these
cells in vivo may be more efficient than in our in vitro system.
However, that CD161MAIT cells were not preferentially in-
fected, and that their numbers were not adversely affected by
incubation with HIV argues against either infection or bystander
cell death being solely responsible for the specific depletion of such
a substantial population of cells.
No recovery of CD161/MAIT cells was seen during 2 years
of HAART. This may be linked to incomplete repair of the bacterial
translocation defect and/or ongoing tissue inflammation, leading to
continued CD161/MAIT cell redistribution with or without
AICD, failure of the precursor pool to proliferate, lack of genera-
tion of new cells from the thymus, or loss of an essential antigen
presenting cell pool or site required for maintenance and/or
expansion. Future studies in different patient groups, for example
pediatric HIV infection, and in different tissues (eg, the liver) may
help dissect these possible mechanisms. The mechanisms leading
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to loss of CD161/MAIT cell populations in early infection and
their failure to recover with HAART are integrated into a model
(supplemental Figure 8).
The loss of the CD161/MAIT cell population in HIV may
have several important consequences. Firstly, it may contribute to
increased susceptibility to M tuberculosis infection. The risk of
tuberculosis doubles within a year of HIV infection, whereas the
CD4 T-cell count remains relatively preserved.54 Recent studies
have provided evidence of a role for MAIT cells in the immune
response to M tuberculosis.9,10 Therefore, in addition to the early
loss of M tuberculosis–specific memory CD4 T cells,7 the loss of
CD161/MAIT cells in acute HIV infection may also contribute
to the increased risk of tuberculosis associated with HIV infection.
Secondly, CD161/MAIT cell loss may also contribute to the risk
of other bacterial and fungal infections. Indeed IL17 has recently
been implicated in the control of mucocutaneous candiasis20 and
invasive nontyphoidal Salmonella enterica infection.22 Finally,
further compromise of the IL17A/IL22 axis, already disrupted
through loss of Th17 cells, may result in increased impairment of
mucosal immunity and contribute to reduced barrier function in
HIV/AIDS, including increased bacterial translocation.
Overall the CD161/MAIT cell population is a highly promi-
nent cell population in the human immune system, and the negative
impact of HIV infection occurs early and is not reversed by
HAART. These data not only provide a novel paradigm for the
immunopathogenesis of HIV but also suggest that future strategies
to rescue or amplify this functional subset could help restore host
defense, including against M tuberculosis.
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